Gold Rate Eases Amid Fears Of Second Wave Of Coronavirus Infections
Gold prices dropped on Monday, as the dollar hovered close to a more than one-week high, despite fears of a second wave of coronavirus infections in Beijing denting risk appetite. Spot gold was down 0.5 per cent at $1,720.56 per ounce as of 0640 GMT. US gold futures slipped 0.7 per cent to $1,725.30 per ounce.
"Gold is caught between two conflicting forces. One is the risk-off force weighing on stocks and industrial commodities and supporting bonds and gold," said Michael McCarthy, chief strategist at CMC Markets.
"But against that we have a stronger US dollar." ​
Gold prices jumped 2.6 per cent last week, marking their best week since April 10, as worries of a new wave of COVID-19 cases clouded hopes of economic recovery.
After weeks with almost no new coronavirus infections, Beijing has recorded dozens of new cases in recent days, while new virus cases and hospitalizations in record numbers swept through more US states.
Rising concerns about a resurgence of the disease dented risk sentiment among investors, sending Asian stock markets and oil prices lower.
"The economy is not doing well, we got COVID-19 again and a low interest rate environment, I think gold remains bid," said Stephen Innes, chief market strategist at financial services firm AxiCorp.
"But, we need significant policy input from the US Federal Reserve or governments to add that fourth level of stimulus to get gold to bounce higher."
Underscoring the impact of the virus, data showed China's industrial output expanded less than expected in May as the country struggles to get back on track.
SPDR Gold Trust holdings rose 0.1 per cent on Friday, while speculators cut their bullish positions in COMEX gold and silver contracts in the week to June 9.
Elsewhere, palladium was down 0.9 per cent at $1,901.68 per ounce, silver fell 2.1 per cent to $17.08, platinum eased 0.2 per cent to $803.77.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.
-
It's Time To Take The GST Council's Bet On Trust Global
Payment records can prove India's services exports, and clear, proportionate rules can bring foreign digital sellers into the tax net.
-
Opinion | India at 38: From Innovation Overperformer to Innovation Powerhouse
India now has 453 VC-backed deep science startups, 18 of them late-stage, after 117 percent growth since 2020. Laurus Labs, at USD 9.3 billion, is the most valuable deep science company in any middle-income economy outside China.